舒芬太尼预处理可降低依托咪酯后的肌阵挛。
Pretreatment with sufentanil reduces myoclonus after etomidate.
作者信息
Hueter L, Schwarzkopf K, Simon M, Bredle D, Fritz H
机构信息
Klinik fuer Anesthesiologie und Intensivtherapie, Friedrich-Schiller-Universitaet Jena, Germany.
出版信息
Acta Anaesthesiol Scand. 2003 Apr;47(4):482-4. doi: 10.1034/j.1399-6576.2003.00081.x.
BACKGROUND
Myoclonic movements are a common problem during the induction of general anesthesia with etomidate. We investigated the influence of pretreatment with the opioid sufentanil on the incidence of etomidate-induced myoclonus.
METHODS
Forty female patients (ASA physical status I-III) were randomly assigned to receive double-blinded either 0.3 micro g kg-1 of sufentanil or placebo 150 s before the induction of sleep with 0.3 mg kg-1 of etomidate. The patients were observed for any myoclonic movement. Grade of dizziness, breathing frequency, non-invasive blood pressure and heart rate were measured during the study period.
RESULTS
None of the 20 patients receiving sufentanil had myoclonic movements after the administration of etomidate, whereas 16 patients in the placebo group (80%) experienced such movements (P<0.01). No cases of apnoea before induction of sleep were seen in the sufentanil group.
CONCLUSION
Sufentanil 0.3 micro g kg-1 is an effective and safe drug to reduce myoclonus after etomidate without causing any harmful side-effect.
背景
使用依托咪酯诱导全身麻醉时，肌阵挛运动是一个常见问题。我们研究了阿片类药物舒芬太尼预处理对依托咪酯诱导的肌阵挛发生率的影响。
方法
40例女性患者（美国麻醉医师协会身体状况分级I - III级）被随机分为两组，在使用0.3mg/kg依托咪酯诱导睡眠前150秒，双盲接受0.3μg/kg舒芬太尼或安慰剂。观察患者是否出现肌阵挛运动。在研究期间测量头晕程度、呼吸频率、无创血压和心率。
结果
接受舒芬太尼的20例患者在给予依托咪酯后均未出现肌阵挛运动，而安慰剂组有16例患者（80%）出现此类运动（P<0.01）。舒芬太尼组在诱导睡眠前未出现呼吸暂停病例。
结论
0.3μg/kg舒芬太尼是一种有效且安全的药物，可减少依托咪酯后的肌阵挛，且不引起任何有害副作用。
Zotero 插件